The management of metastatic castration-resistant prostate cancer (mCRPC) following progression on androgen deprivation therapy (ADT) and an androgen receptor pathway inhibitor (ARPI) represents a complex clinical challenge. Instead, experts must weigh multiple standard options—chemotherapy, lutetium, PARP inhibitors (for susceptible mutations), or immunotherapy (for MSI-high patients)—to provide the best value for individual patients over the entire course of their disease.
The “PSMAfore” Treatment Space
The clinical “PSMAfore” space refers to the first stage of mCRPC after a patient has progressed on an initial ARPI (such as abiraterone, enzalutamide, apalutamide, or darolutamide) used for castration-sensitive disease. Dr. Morris notes that a second-line ARPI is generally ineffective in this setting, as it rarely provides profound or durable anti-cancer effects. When determining the next step, the primary consideration for lutetium therapy is PSMA expression. Because lutetium functions by delivering radiation directly to the tumor, it is not suitable for patients with a low PSMA PET scan. According to Dr. Morris, approximately 10% of patients in this population do not have PSMA-avid disease and should receive chemotherapy instead.
Clinical Factors Influencing Chemotherapy Versus Lutetium
For patients who are PSMA-avid, the decision between chemotherapy and lutetium remains a harder question
due to a lack of randomized data to guide the selection. However, clinical experts look to specific patient features to inform the sequence:
* Visceral Metastasis: Patients with liver metastasis are often considered candidates for upfront chemotherapy, particularly if tumor dosimetry is unclear.
* Biomarkers and Disease Progression: Rapidly progressive disease or the presence of unfavorable genetic markers—specifically p53, RB, and PTEN—often lead clinicians to prioritize chemotherapy.
* PSA Values: A low PSA value relative to the overall burden of disease may also favor an initial chemotherapy approach.
Addressing Disease Volume and Localized Therapy
The spectrum of disease in mCRPC can range from a single lesion to over 100 lesions. This volume significantly influences therapeutic strategy.
Principles of Sequencing and Long-Term Care
The challenge of sequencing is compounded by the fact that treatment efficacy often diminishes as patients progress through subsequent lines of therapy. According to Dr. Ian Davis, the goal of treatment sequencing is to maximize the benefit for the patient across their remaining life, rather than focusing solely on the immediate next intervention. Clinicians must consider whether therapies have independent or interdependent mechanisms of action. If mechanisms are interdependent, the order of administration is critical to ensure patients do not lose the opportunity to benefit from a subsequent treatment. Furthermore, because previous exposures fundamentally alter the biology of the cancer, clinicians must recognize that the magnitude of benefit from agents like docetaxel, abiraterone, or enzalutamide is significantly greater in the hormone-sensitive state than in the later mCRPC state. Ultimately, clinical guidance—including that provided by the NCCN—remains broad, offering a range of choices rather than a rigid, evidence-based roadmap. Physicians are encouraged to focus on the individual patient’s goals, whether that involves improving overall survival, delaying progression, or maintaining quality of life.
Keep reading
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
